Journal Article

DKFZ-2026-01316

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Prognostic role of FDG-PET in patients with relapsed/refractory large B-cell lymphoma treated with CD3-CD20 directed bispecific antibodies: a multicentric analysis.

Wollnitza, S. ; Ventura, D. ; Teichert, M.DKFZ* ; Freisleben, F. ; Boyadzhiev, H. ; Seifert, R. ; Amon, M. ; Barbato, F. ; Scholz, J. K. ; Beck, M. ; Kerkhoff, A. ; Behringer, A. ; Backhaus, P. ; Pohlmann, A. ; Schindler, P. ; Roll, W. ; Müller, F. ; Novak, U. ; Pabst, T. ; Schäfers, M. ; von Tresckow, B.DKFZ* ; Shumilov, E. ; Lenz, G.

2026
Springer-Verl. Heidelberg [u.a.]

Abstract: The clinical use of CD3-CD20-directed bispecific antibodies (BsAbs) has significantly improved outcomes of patients with relapsed/refractory LBCL. However, up to 50% of patients relapse. This study evaluated the prognostic value of longitudinal FDG-PET parameters.58 patients with baseline PET and 45 (78%) with first PET after BsAb initiation were included. Standard PET metrics and Deauville score (DS) were recorded, with percent changes at follow-up defined as ΔPET parameters. Prognostic impact of DS and semi-quantitative PET metrics were determined for PFS/OS.At baseline an whole-body MTV > 504.7 cm³ was associated with shorter median PFS of 1 vs. 3 months (HR = 5.6, P = 0.00025; C-index = 0.94). At first follow-up, those with DS4-5 exhibited significantly higher risk of progression (HR = 11.42, P = 0.0182; C-index = 0.97) and shorter survival (HR = 7.07, P = 0.059; C-index = 0.72). Non-achievement of ≥ 75.5% SUVmean reduction significantly increased risk for PFS (HR = 7.65; p = 0.0065; C-index = 0.92) and OS events (HR = 11.1; p = 0.001; C-index = 0.95).In summary, longitudinal semi-quantitative PET assessment identified patients at high risk of relapse and may enhance risk stratification and personalized management in BsAb-treated patients.

Keyword(s): Deauville-Score ; FDG-PET ; R/r LBCL; BsAb

Note: #DKTKZFB9# / epub

---

Contributing Institute(s):

1. DKTK Koordinierungsstelle Essen/Düsseldorf (ED01)

Research Program(s):

1. 899 - ohne Topic (POF4-899) (POF4-899)

Appears in the scientific report 2026

---

Database coverage:
; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Current Contents - Life Sciences ; DEAL Springer ; DEAL Springer ; Ebsco Academic Search ; Essential Science Indicators ; IF >= 5 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---